Filtered By:
Education: Study
Therapy: Endocrine Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 23 results found since Jan 2013.

Cancers, Vol. 14, Pages 2380: Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells
In this study, we have investigated how alterations in sphingolipids promote cell survival in ET-resistant breast cancer. We have performed LC-MS-based targeted sphingolipidomics of tamoxifen-sensitive and -resistant MCF-7 breast cancer cell lines. Follow-up studies included treatments of cell lines and patient-derived xenograft organoids (PDxO) with small molecule inhibitors; cytometric analyses to measure cell death, proliferation, and apoptosis; siRNA-mediated knockdown; RT-qPCR and Western blot for gene and protein expression; targeted lipid analysis; and lipid addback experiments. We found that tamoxifen-resistant cel...
Source: Cancers - May 12, 2022 Category: Cancer & Oncology Authors: Purab Pal Alec Millner Svetlana E. Semina Rosemary J. Huggins Logan Running Diana S. Aga Debra A. Tonetti Rachel Schiff Geoffrey L. Greene G. Ekin Atilla-Gokcumen Jonna Frasor Tags: Article Source Type: research

Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ER α expression and proliferation in luminal primary and metastatic breast cancer cells
CONCLUSIONS: CHK1 could be considered as an appealing novel pharmacological target for the treatment of luminal primary and MBCs.PMID:35418303 | DOI:10.1186/s13046-022-02360-y
Source: Clinical Breast Cancer - April 14, 2022 Category: Cancer & Oncology Authors: Sara Pescatori Stefano Leone Manuela Cipolletti Stefania Bartoloni Alessandra di Masi Filippo Acconcia Source Type: research

Knockdown of YAP/TAZ sensitizes tamoxifen-resistant MCF7 breast cancer cells
In conclusion, targeting the YAP/TAZ-PSAT1 axis could sensitize tamoxifen-resistant MCF7 breast cancer cells by modulating the mTORC1-survivin axis.PMID:35231654 | DOI:10.1016/j.bbrc.2022.02.083
Source: Biochemical and Biophysical Research communications - March 1, 2022 Category: Biochemistry Authors: Yu Jin Kim Se-Kyeong Jang Sung-Eun Hong Chan Sub Park Min-Ki Seong Hyun-Ah Kim Ki Soo Park Chun-Ho Kim In-Chul Park Hyeon-Ok Jin Source Type: research

Cancers, Vol. 13, Pages 3612: Estrogen Receptor-Alpha and p53 Status as Regulators of AMPK and mTOR in Luminal Breast Cancer
. Das Luminal breast cancer (LBC) driven by dysregulated estrogen receptor-alpha (ERα) signaling accounts for 70% of the breast cancer cases diagnosed. Although endocrine therapy (ET) is effective against LBC, about one-third of these patients fail to respond to therapy owing to acquired or inherent resistance mechanisms. Aberrant signaling via ERα, oncogenes, growth factor receptors, and mutations in tumor suppressors such as p53 impinge on downstream regulators such as AMPK and mTOR. While both AMPK and mTOR have been reported to play important roles in determining sensitivity of LBC to ET, how the ERα-p53 crossta...
Source: Cancers - July 19, 2021 Category: Cancer & Oncology Authors: Nishant Gandhi Chetan C. Oturkar Gokul M. Das Tags: Article Source Type: research

Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells
CONCLUSIONS: Our results suggest that overexpression of TMEM47 in MCF-7 cells acquired TAM resistance to those cells, and knockdown of TMEM47 in TAMR/MCF-7 cells reversed their resistance to TAM. TMEM47 might confer TAM resistance on MCF-7 cells through the inhibition of apoptosis.PMID:33745390 | DOI:10.1177/15330338211004916
Source: Technology in Cancer Research and Treatment - March 22, 2021 Category: Cancer & Oncology Authors: Xin Men Mengyang Su Jun Ma Yueyang Mou Penggao Dai Chao Chen Xi An Cheng Source Type: research

GSE113092 GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer ChIP-seq
Contributors : Jeff S Jasper ; Kimberly J Cocce ; Logan Everett ; Suzanne Wardell ; Thomas Westerling ; Taylor Krebs ; Robert Baldi ; Tricia M Wright ; Alex Yllanes ; Jeremy T Blitzer ; Craig Logsdon ; Daniel Rakiec ; David Ruddy ; Terry Hyslop ; Allison Hall ; Jeffrey R Marks ; Gregory E Crawford ; Myles Brown ; Donald P McdonnellSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensThe estrogen receptor (ER) is expressed in the majority of luminal breast cancers and inhibition of its transcriptional activity with selective estrogen receptor modulators, selective estrogen rec...
Source: GEO: Gene Expression Omnibus - April 13, 2018 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research

GSE108167 GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer DNase hypersensitivity
Contributors : Jeff S Jasper ; Kimberly J Cocce ; Logan Everett ; Suzanne Wardell ; Thomas Westerling ; Taylor Krebs ; Robert Baldi ; Tricia M Wright ; Alex Yllanes ; Jeremy T Blitzer ; Craig Logsdon ; Daniel Rakiec ; David Ruddy ; Terry Hyslop ; Allison Hall ; Jeffrey R Marks ; Gregory E Crawford ; Myles Brown ; Donald P McdonnellSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensThe estrogen receptor (ER) is expressed in the majority of luminal breast cancers and inhibition of its transcriptional activity with selective estrogen receptor modulators, selective estrogen rec...
Source: GEO: Gene Expression Omnibus - December 16, 2017 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research

GSE106695 GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer
Series Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe estrogen receptor (ER) is expressed in the majority of luminal breast cancers and inhibition of its transcriptional activity with selective estrogen receptor modulators, selective estrogen receptor degraders and/or aromatase inhibitors is a standard approach used in the management of this disease. Despite the positive clinical impact of these interventions, de novo and acquired resistance limits the therapeutic lifespan of these classes of drugs. Considering what is known about the complex mechanisms that contribute to the developmen...
Source: GEO: Gene Expression Omnibus - November 20, 2017 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

GSE106694 GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer (RNA-Seq data set 2)
Contributors : Jeff S Jasper ; Kimberly J Cocce ; Logan Everett ; Suzanne Wardell ; Thomas Westerling ; Taylor Krebs ; Robert Baldi ; Tricia M Wright ; Alex Yllanes ; Jeremy T Blitzer ; Craig Logsdon ; Daniel Rakiec ; David Ruddy ; Terry Hyslop ; Allison Hall ; Jeffrey R Marks ; Gregory E Crawford ; Myles Brown ; Donald P McdonnellSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe estrogen receptor (ER) is expressed in the majority of luminal breast cancers and inhibition of its transcriptional activity with selective estrogen receptor modulators, selective estrogen receptor degrader...
Source: GEO: Gene Expression Omnibus - November 20, 2017 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

GSE106681 GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer (RNA-Seq data set 1)
Contributors : Jeff S Jasper ; Kimberly J Cocce ; Logan Everett ; Suzanne Wardell ; Thomas Westerling ; Taylor Krebs ; Robert Baldi ; Tricia M Wright ; Alex Yllanes ; Jeremy T Blitzer ; Craig Logsdon ; Daniel Rakiec ; David Ruddy ; Terry Hyslop ; Allison Hall ; Jeffrey R Marks ; Gregory E Crawford ; Myles Brown ; Donald P McdonnellSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe estrogen receptor (ER) is expressed in the majority of luminal breast cancers and inhibition of its transcriptional activity with selective estrogen receptor modulators, selective estrogen receptor degrader...
Source: GEO: Gene Expression Omnibus - November 20, 2017 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research